Novel effects of TKI inhibitors in Parkinson’s disease


A new study has reported that nilotinib, a tyrosine kinase inhibitor (TKI), alters brain dopamine metabolism and significantly reduces plasma total alpha-synuclein in patients with Parkinson’s disease (Pagan et al. Pharm Res Perspect 2019; epublished March 12, 2019; free full text at

Nilotinib (Tasigna) is a small-molecule TKI that targets breakpoint cluster/Abelson (BCR-Abl) and is approved to treat chronic myelogenous leukemia (CML) at a dose of 300-400 mg BID. Other agents in this class include imatinib (Gleevec), ponatinib (Iclusig) and bafetinib (INNO-406, a BCR-Abl/Lyn TKI).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page